A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Safety, Tolerability and Antiviral Activity of 12 Weeks' Treatment With a New Antiviral HCMV Drug.
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Letermovir (Primary)
- Indications Cytomegalic inclusion disorders
- Focus Therapeutic Use
- 27 Dec 2012 New source identified and integrated (German Clinical Trials Register; DRKS00003835).
- 12 Sep 2012 Results presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 31 Mar 2012 Primary endpoint 'Time-to-treatment-failure' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History